Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA4 | P22748 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 3/20 | 0.41 |
| ▸ | CES1 | P23141 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12817090 | 0.80 | CA1 (0.40) | CA1CA2CA4CA12CA7 | |
| SCHEMBL7702552 | 0.72 | CA1 (0.43) | CA1CA2CA4CA12CA7 | |
| SCHEMBL41646 | 0.72 | CA1 (0.43) | CA1CA2CA4CA12CA7 | |
| SCHEMBL186507 | 0.71 | CES2 (0.48) | CA1CA2CA4CA12CA7 | |
| SCHEMBL295026 | 0.71 | CA1 (0.38) | CA1CA2CA4CA12CA7 | |
| Formaldehyde SCHEMBL27280878 | 0.71 | CA1 (0.43) | CA1CA2CA4CA12CA7 | |
| SCHEMBL23589702 | 0.69 | CA1 (0.41) | CA1CA2CA4CA12CA7 | |
| SCHEMBL6470270 | 0.69 | CA1 (0.41) | CA1CA2CA4CA12CA7 | |
| Bromide SCHEMBL6247121 | 0.69 | CA1 (0.41) | CA1CA2CA4CA12CA7 | |
| SCHEMBL31540317 | 0.69 | CA1 (0.41) | CA1CA2CA4CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 364 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118265545-A | Asymmetric bisbenzimidazole STING agonist immunoconjugates and uses thereof | 博尔特生物治疗药物有限公司 | 2024-06-28 | — | — | CN | claimed |
| WO-2024137619-A1 | ANTI-CLAUDIN, BIS-BENZIMID AZOLE STING AGONIST IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2024-06-27 | — | — | WO | claimed |
| US-20240197899-A1 | 2-AMINO-4-CARBOXAMIDE-BENZAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2024-06-20 | — | — | US | claimed |
| WO-2024129956-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2024-06-20 | — | — | WO | claimed |
| EP-4373891-A2 | AZAINDOLE CYANINE DYES, USES, AND METHODS OF PREPARATION | Life Technologies Corporation (US) | 2024-05-29 | — | — | EP | claimed |
| CN-117794583-A | Bisbenzimidazole STING agonist immunoconjugates and uses thereof | 博尔特生物治疗药物有限公司 | 2024-03-29 | — | — | CN | claimed |
| CN-117529529-A | Azaindole cyanine dye, application and preparation method | 生命技术公司 | 2024-02-06 | — | — | CN | claimed |
| WO-2023225534-A1 | AROMATIC BORON-CONTAINING COMPOUNDS AND RELATED INSULIN ANALOGS | PROTOMER TECHNOLOGIES INC. (US) | 2023-11-23 | — | — | WO | claimed |
| US-20230374045-A1 | AROMATIC BORON-CONTAINING COMPOUNDS AND RELATED INSULIN ANALOGS | PROTOMER TECHNOLOGIES INC. | 2023-11-23 | — | — | US | claimed |
| US-20230293716-A1 | ELASTASE-SUBSTRATE, PEPTIDE LINKER IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | claimed |
| US-20120156140-A1 | FLUORESCENT COMPOUNDS | DYOMICS GMBH (DE) | 2012-06-21 | — | — | US | claimed |
| US-20100317045-A1 | COMPOUNDS USED AS DYES COMPERABLE TO ALEXA FLUOR 350 DYES | PIERCE BIOTECHNOLOGY, INC. (US) | 2010-12-16 | — | — | US | claimed |
| EP-1792949-B1 | Hydrophilic marker on the basis of diastereomeric cyanines | DYOMICS GMBH (DE) | 2010-09-08 | — | — | EP | claimed |
| US-7612091-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-03 | — | — | US | claimed |
| EP-1792949-A2 | Hydrophilic marker on the basis of diastereomeric cyanines | Dyomics GmbH (DE) | 2007-06-06 | — | — | EP | claimed |
| US-20040192612-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-09-30 | — | — | US | claimed |
| US-6084102-A | THE OLIGONUCLEOTIDE IS COMPLEMENTARY TO A TARGET SEQUENCE OF SINGLE STRANDED OR DOUBLE STRANDED DNA, RNA OR HYBRIDS AND, WHEN USED AS A PROBE, BINDS MORE STRONGLY BECAUSE OF THE BOUND MINOR GROVE BINDER; MEDICAL DIAGNOSIS; ANTISENSE THERAPY | EPOCH PHARMACEUTICALS, INC. (US) | 2000-07-04 | — | — | US | claimed |
| US-6072046-A | SELECTIVELY FORM TRIPLEXES WITH A COMPLEMENTARY TARGET SEQUENCE IN DOUBLE-STRANDED DNA AND EFFICIENTLY CROSSLINK WITH BOTH STRANDS; THERAPEUTICS, DIAGNOSTICS, AND GENETIC PROBES | EPOCH PHARMACEUTICALS, INC. (US) | 2000-06-06 | — | — | US | claimed |
| WO-2000012523-A1 | DIAZIRIDINYL-ARYL AND BIS-[DI(CHLOROETHYL)AMINO]-ARYL OLIGONUCLEOTIDE CONJUGATES AND REAGENTS FOR MAKING THE SAME | EPOCH PHARMACEUTICALS, INC. (US) | 2000-03-09 | — | — | WO | claimed |
| US-5746997-A | Radiohalogenation of oligonucleotides via trialkylstannylaryl conjugates | EPOCH PHARMACEUTICALS, INC. (US) | 1998-05-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317045-A1 | COMPOUNDS USED AS DYES COMPERABLE TO ALEXA FLUOR 350 DYES | ACR, RO60, ARF5 | CA1 2168/4885CA2 1667/4885CA4 422/4885 |
| US-20120156140-A1 | FLUORESCENT COMPOUNDS | NCL, FUS, EFTUD2 | CA1 3764/4885CA2 4187/4885CA4 2512/4885 |
| US-20230293716-A1 | ELASTASE-SUBSTRATE, PEPTIDE LINKER IMMUNOCONJUGATES, AND USES THEREOF | SERPINB1, ELANE, CELA1 | CA1 1675/4885CA2 3303/4885CA4 1487/4885 |
| US-20040192612-A1 | Caspase inhibitors and uses thereof | CASP1, CASP3, CASP5 | CA1 321/4885CA2 465/4885CA4 1092/4885 |
| US-20240197899-A1 | 2-AMINO-4-CARBOXAMIDE-BENZAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | AADAC, BRD4, IDO2 | CA1 460/4885CA2 574/4885CA4 276/4885 |
| US-20230374045-A1 | AROMATIC BORON-CONTAINING COMPOUNDS AND RELATED INSULIN ANALOGS | IAPP, GPR119, INSR | CA1 4652/4885CA2 2869/4885CA4 2326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.